Navigation Links
ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials
Date:8/27/2007

PARIS, August 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, today announced that its drug discovery collaboration with Allergan Inc. (NYSE: AGN), a global speciality pharmaceutical and medical device company, has reached a success milestone. As a result of the efforts of the Allergan and ExonHit research team, human clinical testing will be initiated on the first collaboration New Chemical Entity (NCE). This NCE (designated EHT/AGN001) has a novel mechanism of action and will enter a phase I study later this year.

The objectives of Allergan and ExonHit's strategic collaboration are to identify, develop and commercialise drugs targeted at the treatment of neurodegenerative diseases, pain and ophthalmology. The collaboration was initiated in 2003 and has been extended twice as a consequence of its good productivity.

"We are happy to see that this collaboration has lead to a clinical candidate in such a short period of time. This success is a result of the dedicated efforts and focus by the research teams from both companies," said Dr. Scott Whitcup, Executive Vice President, Research & Development of Allergan Inc.

"By industry standards, this collaboration's productivity is exceptional, delivering a clinical product in less than four years together with two other innovative pre-clinical projects," stated Bruno Tocque President of the Management Board of ExonHit. He added "I would like to express my gratitude to our scientists who have developed a drug discovery engine enabling this achievement".

Under the terms of the agreement, Allergan will assume responsibility for the ongoing clinical development and commercialisation of EHT/AGN001. Contingent upon
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in high pressure ... 2000, which is ideal for new applications for processing ... . This compact laboratory homogenizer is the perfect solution ... additives and ingredients as well as for the ...
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Ltd,(SWX: ARPN) announced today its financial results for the ... pipeline progress:, - Second pivotal Phase III trial ... as did the first, - Submission of New ... - First patients enrolled in a Phase II trial ...
... DALLAS, March 13 BioMagnetics Diagnostics Corp. (Pink,Sheets: ... price target of $1.42,by Beacon Equity Research Analyst, ... available at http://www.BeaconEquity.com ., Anyone interested ... members@beaconequity.com with "BMGP" in,the subject line., ...
... A study published online today in Genome ... the evolutionary conservation of the genes and pathways associated ... conserved aging-related genes in simple model organisms that may ... role in human aging and age-associated diseases. , While ...
Cached Biology Technology:Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9BioMagnetics Diagnostics Corp. Rated 'Speculative Buy,' Target Price $1.42 by Beacon Equity Research 2Growing old together: Yeast, worms and people may age by similar mechanisms 2
(Date:12/24/2014)... in December 2014, the 1U™ app has helped ... remember their usernames and passwords through replacing the antiquated system ... people who have struggled to remember usernames and passwords, ... on redefining identity, announced today that it is offering the ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... America Perimeter Security Systems Market" report to their offering. ... North American perimeter security market is estimated to grow at ... U.S. market holds a larger share in this market, ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... distinguished professor, dean of the College of Engineering at ... who has devoted over 25 years to enhancing IEEE,s ... members and industry, is being honored with the 2010 ... largest professional association advancing technology for humanity. , "I ...
... 2010 - Haze, scientifically known as atmospheric aerosols - ... a major environmental problem because it degrades visibility, affects ... impacts, how the haze is formed is not fully ... sciences and chemistry who has studied air chemistry for ...
... world is a cooler, wetter place because of flowering ... the journal Proceedings of the Royal Society B ... basin, where replacing flowering plants with non-flowering varieties would ... covered by ever-wet rainforest. The simulations demonstrate the ...
Cached Biology News:Dean of the UM College of Engineering to receive 2010 IEEE Richard M. Emberson Award 2Dean of the UM College of Engineering to receive 2010 IEEE Richard M. Emberson Award 3Research is getting closer to understanding critical nucleus in haze formation, prof says 2Flower power makes tropics cooler, wetter 2Flower power makes tropics cooler, wetter 3
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: